Literature DB >> 10719142

Evidence for a compromised dorsolateral prefrontal cortical parallel circuit in schizophrenia.

W E Bunney1, B G Bunney.   

Abstract

Evidence is reviewed that one of the cognitive-affective parallel circuits in the brain, the dorsolateral prefrontal circuit, is compromised at the level of anatomical, neuropathological and transmitter-related molecules in a subgroup of schizophrenic patients. The dorsolateral prefrontal cortex (DLPFC) comprises a key structure in this circuit. Data supporting a compromised DLPFC includes cognitive deficits, decreased regional metabolism and blood flow activation; disruption of cortical subplate activity (inferred from maldistribution of neurons from the cortical subplate which are required for the orderly neuronal migration during the second trimester and for connectivity of the thalamocortical neurons); decrease in major components of the cortical inhibitory neurotransmitter system; and alterations in the molecules critical for NMDA-receptor mediated neural transmission. Thus a great deal of evidence accumulated over the last decade has definitively implicated the dorsolateral prefrontal cortex in the pathophysiology of schizophrenia. Emerging data also confirms neuropathology in the mediodorsal nucleus of the thalamus that projects to the DLPFC. There is currently a consensus that schizophrenia involves epigenetic factors interacting with genetic information in the cells to produce abnormal molecules which when they are associated with abnormal circuits such as the DLPFC, may result in abnormal behavior. Thus, abnormal cortical connections and or altered neurotransmitter related molecules in the DLPFC could explain some of the prominent frontal cognitive disruptions seen in schizophrenia.

Entities:  

Mesh:

Year:  2000        PMID: 10719142     DOI: 10.1016/s0165-0173(99)00031-4

Source DB:  PubMed          Journal:  Brain Res Brain Res Rev


  55 in total

1.  Effects of phencyclidine (PCP) and MK 801 on the EEGq in the prefrontal cortex of conscious rats; antagonism by clozapine, and antagonists of AMPA-, alpha(1)- and 5-HT(2A)-receptors.

Authors:  Claude Sebban; Brigitte Tesolin-Decros; Jorge Ciprian-Ollivier; Laurent Perret; Michael Spedding
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

Review 2.  Subcortical white matter interstitial cells: their connections, neurochemical specialization, and role in the histogenesis of the cortex.

Authors:  V E Okhotin; S G Kalinichenko
Journal:  Neurosci Behav Physiol       Date:  2003-02

3.  Molecular and cellular evidence for an oligodendrocyte abnormality in schizophrenia.

Authors:  Patrick R Hof; Vahram Haroutunian; Christina Copland; Kenneth L Davis; Joseph D Buxbaum
Journal:  Neurochem Res       Date:  2002-10       Impact factor: 3.996

4.  Spontaneous brain activity observed with functional magnetic resonance imaging as a potential biomarker in neuropsychiatric disorders.

Authors:  Yuan Zhou; Kun Wang; Yong Liu; Ming Song; Sonya W Song; Tianzi Jiang
Journal:  Cogn Neurodyn       Date:  2010-08-03       Impact factor: 5.082

Review 5.  Matrix Metalloproteinase-9 as a Novel Player in Synaptic Plasticity and Schizophrenia.

Authors:  Katarzyna Lepeta; Leszek Kaczmarek
Journal:  Schizophr Bull       Date:  2015-04-02       Impact factor: 9.306

6.  Error monitoring dysfunction across the illness course of schizophrenia.

Authors:  Veronica B Perez; Judith M Ford; Brian J Roach; Scott W Woods; Thomas H McGlashan; Vinod H Srihari; Rachel L Loewy; Sophia Vinogradov; Daniel H Mathalon
Journal:  J Abnorm Psychol       Date:  2011-11-07

7.  Comprehensive analysis of polymorphisms throughout GAD1 gene: a family-based association study in schizophrenia.

Authors:  J Du; S Duan; H Wang; W Chen; X Zhao; A Zhang; L Wang; J Xuan; L Yu; S Wu; W Tang; X Li; H Li; G Feng; Q Xing; L He
Journal:  J Neural Transm (Vienna)       Date:  2008-03-12       Impact factor: 3.575

Review 8.  Potential microbial origins of schizophrenia and their treatments.

Authors:  S Hossein Fatemi
Journal:  Drugs Today (Barc)       Date:  2009-04       Impact factor: 2.245

Review 9.  Treatment of cognitive deficits associated with schizophrenia: potential role of catechol-O-methyltransferase inhibitors.

Authors:  José A Apud; Daniel R Weinberger
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

10.  Thalamo-frontal white matter alterations in chronic schizophrenia: a quantitative diffusion tractography study.

Authors:  Jungsu S Oh; Marek Kubicki; Gudrun Rosenberger; Sylvain Bouix; James J Levitt; Robert W McCarley; Carl-Fredrik Westin; Martha E Shenton
Journal:  Hum Brain Mapp       Date:  2009-11       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.